ALPHA study: First-in-human data of ALLO-501 and ALLO-647 in R/R large B-cell or follicular lymphoma

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the GvHD Hub was pleased to speak to Sattva Neelapu, MD Anderson Cancer Center, Houston, US. In this video, he discusses the first-in-human data of the ALPHA study (NCT03939026). This was a phase I, open-label, multicenter study of ALLO-501, an anti-CD19 allogeneic CAR T-cell therapy and ALLO-647, a CD53 monoclonal antibody, in patients with relapsed/refractory large B-cell or follicular lymphoma.

Sattva Neelapu describes the novelty of the products and the study design before discussing the safety and efficacy results of the 22 patients enrolled, at the time of data cutoff. To be successful they aimed to prevent graft-versus-host disease as well as delay/stop the rejection of the donor CAR T cells. This combination treatment was fairly well tolerated; however, the dose-escalation study is still ongoing.